Log in to search using one of your social media accounts:

 

Rapid hepatitis C testing may help better screen young adults
(Boston Medical Center) Routine and rapid hepatitis C virus testing among young adults who use injection drugs improves life expectancy and may provide a good use of limited resources, according to new research out of Boston Medical Center, in partnership with the Boston Public Health Commission. The findings are published online ahead of print in the journal Clinical Infectious Diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 21, 2017 Category: International Medicine & Public Health Source Type: news

Hepatitis C Quiz: What is Hepatitis C?
Title: Hepatitis C Quiz: What is Hepatitis C?Category: MedicineNet QuizCreated: 6/19/2013 12:00:00 AMLast Editorial Review: 9/20/2017 1:09:27 PM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - September 20, 2017 Category: Nutrition Source Type: news

DNDi welcomes Malaysia's move to secure access to more affordable hepatitis C treatments
(Drugs for Neglected Diseases Initiative) Malaysia has issued a 'government use' licence enabling access to more affordable versions of an expensive and patented medicine to treat hepatitis C. This landmark decision should help the more than 400,000 people living with hepatitis C in Malaysia access sofosbuvir, and could have important repercussions in the global effort to secure access to expensive treatments for this viral disease. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 20, 2017 Category: Infectious Diseases Source Type: news

Costly Drugs to Weigh on U.S. Employers' Expenses in 2018 - Survey Costly Drugs to Weigh on U.S. Employers' Expenses in 2018 - Survey
U.S. employers are bracing for higher health care expenses in 2018 as spending on new drugs to treat diseases such as cancer, multiple sclerosis and hepatitis C is expected to rise more than 7%, according to consultancy firm Mercer.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2017 Category: Consumer Health News Tags: Internal Medicine News Source Type: news

Costly drugs to weigh on U.S. employers' expenses in 2018: survey
(Reuters) - U.S. employers are bracing for higher health care expenses in 2018 as spending on new drugs to treat diseases such as cancer, multiple sclerosis and hepatitis C is expected to rise more than 7 percent, according to consultancy firm Mercer. (Source: Reuters: Health)
Source: Reuters: Health - September 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

England's NHS can't afford Big Pharma: They will only pay for a new Hep C treatment if the patient is cured
(Natural News) England’s National Health Service (NHS) is showing signs that it is cash-strapped: It has recently announced that it will no longer automatically shoulder payment for the treatment of its citizens who are Hepatitis C-afflicted; it will only do so once the patient is cured. Those who are lucky enough to get cured will have their... (Source: NaturalNews.com)
Source: NaturalNews.com - September 18, 2017 Category: Consumer Health News Source Type: news

'Exciting' discovery on path to develop new type of vaccine to treat global viruses
Scientists at the University of Southampton have made a significant discovery in efforts to develop a vaccine against Zika, dengue and Hepatitis C viruses that affect millions of people around the world. In a study published in Science Immunology, researchers have shown that natural killer cells (NK cells), which are a fundamental part of the body's immune system, can recognise many different viruses including global pathogens such as Zika, dengue and Hepatitis C viruses, through a single receptor called KIR2DS2. (Source: World Pharma News)
Source: World Pharma News - September 15, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

'Exciting' discovery on path to develop new type of vaccine to treat global viruses
(University of Southampton) Scientists at the University of Southampton have made a significant discovery in efforts to develop a vaccine against Zika, dengue and Hepatitis C viruses that affect millions of people around the world. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 15, 2017 Category: International Medicine & Public Health Source Type: news

Sofosbuvir Safe, Effective for HCV in Those With CKD Sofosbuvir Safe, Effective for HCV in Those With CKD
Sofosbuvir-based antiviral therapy cured hepatitis C virus infection in more than 80% of patients with chronic kidney disease, a retrospective cohort study found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Tattoo ink particles can spread into lymph nodes
Conclusion If you already have a tattoo, there's nothing in this study that should alarm you. It doesn't show that people with tattoos are more likely to get cancer, despite the scaremongering headlines. The researchers explain how tattoo pigments are picked up as "foreign bodies" by the body's immune system and are then stored in the skin and lymph nodes. But they can't tell us what effects this process has on our health. The researchers weren't told any medical information about the donor samples, such as any diseases they had (including cancer) or the cause of donors' deaths. The study also has other limitatio...
Source: NHS News Feed - September 14, 2017 Category: Consumer Health News Tags: Lifestyle/exercise Source Type: news

A Public Health Approach to Hepatitis C in an Urban Setting A Public Health Approach to Hepatitis C in an Urban Setting
This study describes the rationale for and components of a public health approach to HCV infection in New York City.American Journal of Public Health (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 14, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Electronic health record alert improves HCV screening and treatment among baby boomers
(Wiley) In a recent study, screening rates for hepatitis C virus (HCV) infection among baby boomers increased fivefold in the year following implementation of an electronic health record (EHR)-based prompt for primary care physicians. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 14, 2017 Category: Infectious Diseases Source Type: news

Janssen to stop further development of JNJ-4178 hepatitis C treatment
Janssen Sciences Ireland has taken a strategic decision to discontinue further development of its investigational regimen JNJ-4178 for the treatment of patients with hepatitis C. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news

Aethlon Medical wins FDA EAP designation for Hemopurifier
Aethlon Medical (NSDQ:AEMD) said today it received an Expedited Access Pathway designation for its Aethlon Hemopurifier designed for treating life-threatening viruses. The San Diego-based company said its Hemopurifier has been validated to capture a “broad spectrum of viruses that are highly glycosylated”, which includes lethal strains of pandemic influenza, mosquito-borne viruses and hemorrhagic viruses with no currently approved treatment. “We are honored to have our Hemopurifier designated to the Expedited Access Pathway and additionally are pleased that FDA has also allowed our proposed &ldq...
Source: Mass Device - September 12, 2017 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Food & Drug Administration (FDA) Regulatory/Compliance Aethlon Medical Inc. Source Type: news

Johnson & Johnson arm halts R & D on Hepatitis C drug
​​Instead, the company will focus on a cure for chronic hepatitis B, an inflammation of the liver caused by a different virus. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 11, 2017 Category: Pharmaceuticals Source Type: news

Janssen to Discontinue Hepatitis C Development Program
Viral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B (Source: Johnson and Johnson)
Source: Johnson and Johnson - September 11, 2017 Category: Pharmaceuticals Source Type: news

J & J unit ends hepatitis C drug development in crowded market
(Reuters) - Janssen Sciences Ireland UC, a unit of Johnson& Johnson, said it would discontinue further development of its hepatitis C research, citing increased availability of a number of effective hepatitis C therapies. (Source: Reuters: Health)
Source: Reuters: Health - September 11, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Comparison of ICD-9 codes for depression and alcohol misuse to survey instruments suggests these codes should be used with caution - Boscarino JA, Moorman AC, Rupp LB, Zhou Y, Lu M, Teshale EH, Gordon SC, Spradling PR, Schmidt MA, Trinacty CM, Zhong Y, Holmberg SD, Holtzman D.
BACKGROUND: Research suggests depression and alcohol misuse are highly prevalent among chronic hepatitis C (CHC) patients, which is of clinical concern. AIMS: To compare ICD-9 codes for depression and alcohol misuse to validated survey instruments. ... (Source: SafetyLit)
Source: SafetyLit - September 9, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

As hepatitis C flared in former Soviet republic, Gilead saw an opportunity
The company has taken heat for the price of its hepatitis C drugs, but this artist enshrined the company's work in his home country to eradicate the virus. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 8, 2017 Category: American Health Authors: Ron Leuty Source Type: news

As hepatitis C flared in former Soviet republic, Gilead saw an opportunity
The company has taken heat for the price of its hepatitis C drugs, but this artist enshrined the company's work in his home country to eradicate the virus. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 8, 2017 Category: Biotechnology Authors: Ron Leuty Source Type: news

People who use drugs require prioritization, not exclusion, in HCV elimination
(International Network for Hepatitis C in Substance Users) An international conference bringing together hepatitis C experts from around the world is today calling for strategies to prioritise people who use drugs, saying hepatitis C elimination is impossible without them. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - September 6, 2017 Category: International Medicine & Public Health Source Type: news

Gilead to Buy Kite for Promising Cancer Therapies in $12 Billion Deal Gilead to Buy Kite for Promising Cancer Therapies in $12 Billion Deal
Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Syringe Exchange Program Aims To Slow Hepatitis C Infections In Alaska
Highlights the work of a syringe exchange program in Alaska and the impacts of these types of exchange programs generally. Among Alaskans 18-29, the hepatitis C rate doubled between 2011 and 2015. In some rural areas, hepatitis C rates have increased by 490%. With only four exchange programs in the state, people in small towns often have limited access to clean syringes. Hepatitis C is also extremely expensive to treat. This exchange program could operate for nearly a year for the cost of curing one person with hepatitis C. (Source: News stories via the Rural Assistance Center)
Source: News stories via the Rural Assistance Center - August 29, 2017 Category: Rural Health Source Type: news

With Opioid Crisis, a Surge in Hepatitis C
n an unrelenting opioid epidemic, hepatitis C is infecting tens of thousands of mostly young, white injection drug users, with the highest prevalence in the same Appalachian, Midwestern and New England states that are seeing the steepest overdose death rates. (Source: PHPartners.org)
Source: PHPartners.org - August 28, 2017 Category: International Medicine & Public Health Source Type: news

Gilead-Kite: A Breakthrough. A $12 Billion Deal. Another Expensive Drug
Gilead Sciences, the leading maker of drugs for HIV and hepatitis C, is making a gutsy move into the cutting edge of cancer treatment, spending $11.9 billion in cash to buy Kite Pharma, developer of a treatment that attacks tumors by genetically modifying patients ’ own white blood cells. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 28, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:GILD NASDAQ:KITE NASDAQ:JUNO Source Type: news

Curexa ® Pharmacy dispensing Mavyret ™ for the treatment of chronic...
Curexa® Pharmacy proudly announces the availability of MAVYRET™. MAVYRET™ (glecaprevir and pibrentasvir) is a newly approved chronic Hepatitis C oral therapy.(PRWeb August 28, 2017)Read the full story at http://www.prweb.com/releases/2017/08/prweb14634795.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 28, 2017 Category: Pharmaceuticals Source Type: news

Curexa ® Pharmacy Dispensing Vosevi ™ for the Treatment of Chronic...
Curexa® Pharmacy proudly announces the availability of VOSEVI™. VOSEVI™ (sofosbuvir, velpatasvir, and voxilaprevir) is a newly approved chronic Hepatitis C oral therapy.(PRWeb August 28, 2017)Read the full story at http://www.prweb.com/releases/2017/08/prweb14634832.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 28, 2017 Category: Pharmaceuticals Source Type: news

Women who inject drugs may be at greater risk of HCV than men
©istock.com/praetorianphoto There is a clear body of research assessing sex and gender differences in risk behaviors among people who inject drugs, however little or no research has investigated sex differences in hepatitis C (HCV) susceptibility. A newly published analysis examining data from... (Source: NIDA News)
Source: NIDA News - August 25, 2017 Category: Addiction Tags: Men, Prevention Research, Researchers, Women, Women and Drugs Source Type: news

"I love having benzos after my coke shot": the use of psychotropic medication among cocaine users in downtown Montreal - Motta-Ochoa R, Bertrand K, Arruda N, Jutras-Aswad D, Roy E.
BACKGROUND: Cocaine abuse is a major public health issue due to its role in the HIV and hepatitis C virus (HCV) epidemics in North America. A significant area of concern among people who use cocaine (PWUC), injected or smoked, is their frequent misuse of p... (Source: SafetyLit)
Source: SafetyLit - August 24, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Shorter Anti-HCV Regimen Effective in Patients With or Without Cirrhosis Shorter Anti-HCV Regimen Effective in Patients With or Without Cirrhosis
An eight-week regimen containing grazoprevir-ruzasvir-uprifosbuvir appears to be effective for treating hepatitis C virus (HCV) infection in patients with or without cirrhosis, according to findings from a pair of randomized phase 2 open-label trials.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 21, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Public Policy Awards: Addressing HIV and/or Hepatitis C in the Context of Local U.S. Opioid Epidemics
Funding for organizations working at the state or local level on efforts to address HIV and/or hepatitis C in the context of the opioid epidemic. (Source: PHPartners.org)
Source: PHPartners.org - August 21, 2017 Category: International Medicine & Public Health Source Type: news

DAA Combination for Elderly Patients With Chronic Hepatitis C DAA Combination for Elderly Patients With Chronic Hepatitis C
This study aimed to assess the cost-effectiveness of direct-acting antivirals for the treatment of chronic hepatitis C in elderly patients. Which patients should be considered for treatment?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 16, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

WVU Researchers, Health Professionals Lead New Effort to Prevent HIV and Hepatitis C Outbreaks Related to Opioid Epidemic
West Virginia has the highest drug overdose fatality and hepatitis rates in the U.S., which makes them particularly vulnerable to outbreaks of HIV, especially because local health systems in rural areas may not have the ability to address an outbreak. Led by West Virginia University, the Rural West Virginia Responds to Opioid Injection Epidemics: From Data to Action project is developing an integrated prevention, harm reduction, and treatment team to rapidly identify and mitigate small HIV "microepidemics" in eight southern West Virginia counties. (Source: News stories via the Rural Assistance Center)
Source: News stories via the Rural Assistance Center - August 16, 2017 Category: Rural Health Source Type: news

Newly Approved Hepatitis C Drug Has High Response Rates (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM Nearly all patients with chronic hepatitis C virus (HCV) infection treated with glecaprevir-pibrentasvir achieved sustained virologic response after 12 weeks … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 16, 2017 Category: Primary Care Source Type: news

How Do Direct-Acting Antivirals for HCV Affect HCC Risk? How Do Direct-Acting Antivirals for HCV Affect HCC Risk?
The latest data on the controversial hepatitis C-hepatocellular carcinoma treatment link are examined.Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 15, 2017 Category: Consumer Health News Tags: Gastroenterology Commentary Source Type: news

Medical News Today: How is hepatitis C transmitted?
In this article, learn about how hepatitis C is transmitted, the types of hepatitis, their symptoms, and how to prevent transmission of the virus. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 12, 2017 Category: Consumer Health News Tags: Liver Disease / Hepatitis Source Type: news

BioPlus Specialty Pharmacy Has Available Mavyret: the Newly FDA...
BioPlus Specialty Pharmacy, one of the nation’s leading innovative specialty pharmacies, can prescribe the newly approved Mavyret to treat all genotypes of hepatitis C.(PRWeb August 09, 2017)Read the full story at http://www.prweb.com/releases/2017/08/prweb14584075.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 9, 2017 Category: Pharmaceuticals Source Type: news

MAVYRET ™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C
MAVYRET ™ (glecaprevir/pibrentasvir) was developed by US-based biopharmaceutical company AbbVie as a pan-genotypic treatment for adults suffering from chronic hepatitis C virus (HCV) infection across six major genotypes (GT1 to GT6). (Source: Drug Development Technology)
Source: Drug Development Technology - August 8, 2017 Category: Pharmaceuticals Source Type: news

Nonspecialists Could Safely Provide Hepatitis C Care (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Nonspecialists can safely manage the care of patients with chronic hepatitis C virus (HCV) infection who take direct-acting … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 8, 2017 Category: Primary Care Source Type: news

KloudScript ™ Specialty Network, Now Dispensing Vosevi™ and Mavyret™
KloudScript expands Hepatitis C therapeutic category to include Vosevi™ and Mavyret™(PRWeb August 08, 2017)Read the full story at http://www.prweb.com/releases/2017/08/prweb14580864.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 8, 2017 Category: Pharmaceuticals Source Type: news

PCPs Can Effectively Manage HCV Care With New Drugs PCPs Can Effectively Manage HCV Care With New Drugs
Primary care providers and nurse practitioners can safely and effectively manage care for patients with hepatitis C virus, using new drugs.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 7, 2017 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

FDA Approves Mavyret for Hepatitis C
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - August 7, 2017 Category: General Medicine Source Type: news

Mavyret Approved for Hepatitis C
Title: Mavyret Approved for Hepatitis CCategory: Health NewsCreated: 8/4/2017 12:00:00 AMLast Editorial Review: 8/7/2017 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - August 7, 2017 Category: Nutrition Source Type: news

New 8-Week Treatment Approved for All Hepatitis C Genotypes (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and Andr é Sofair, MD, MPH The FDA has approved the first 8-week treatment for chronic hepatitis C genotypes 1 through 6 in patients … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 7, 2017 Category: Primary Care Source Type: news

FDA approves new drug to treat hepatitis C
The new drug can treat all forms of hepatitis C in as little as eight weeks (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - August 4, 2017 Category: Consumer Health News Source Type: news

Mavyret Approved for Hepatitis C
A chronic viral infection of the liver Source: HealthDay Related MedlinePlus Pages: Hepatitis C, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 4, 2017 Category: Consumer Health News Source Type: news

Mavyret Approved for Hepatitis C
FRIDAY, Aug. 4, 2017 --Mavyret (glecaprevir and pibrentasvir) has been approved by the U.S. Food and Drug Administration to treat adults with certain types of chronic hepatitis C virus (HCV). The combination drug is the first approved therapy for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 4, 2017 Category: General Medicine Source Type: news

Africa: New Medication for Hepatitis C Targeting Africa
[East African] Scientists have come up with a new treatment for hepatitis C targeting resource-limited countries, especially those in sub-Saharan Africa. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 4, 2017 Category: African Health Source Type: news

FDA OKs 8-Week Mavyret for Hepatitis C FDA OKs 8-Week Mavyret for Hepatitis C
Glecaprevir/pibrentasvir is the first HCV treatment of this duration approved for genotypes 1 through 6 in previously untreated adults without cirrhosis.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 3, 2017 Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news

FDA OKs new drug to treat all forms of hepatitis C
U.S. regulators have approved a new drug to treat all forms of hepatitis C. (Source: ABC News: Health)
Source: ABC News: Health - August 3, 2017 Category: Consumer Health News Tags: Health Source Type: news